Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$41.15 USD
-0.76 (-1.81%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $41.14 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Tarsus Pharmaceuticals, Inc. has a market cap of $1.76B, which represents its share price of $41.91 multiplied by its outstanding shares number of 42.01M. As a small-cap company, TARS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TARS 41.15 -0.76(-1.81%)
Will TARS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Other News for TARS
Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result
Short Report: Grindr shorts at record highs as CFO quits before earnings
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | TARS ...
ClearBridge Small Cap Strategy Q2 2025 Commentary